Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Posttransplantation lymphoproliferative disorders (PTLD): current perspectives

M A Nalesnik1

  • 1Division of Transplantation Pathology, University of Pittsburgh Medical Center, PA 15213, USA.

Seminars in Thoracic and Cardiovascular Surgery
|April 1, 1996
PubMed
Summary

Posttransplant lymphoproliferative disorders (PTLDs) are lymphoid conditions arising after organ transplantation due to immunosuppression, often linked to Epstein-Barr virus (EBV). Individualized therapy is crucial given their diverse clinical presentations and outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Communication gaps associated with donor-derived infections.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

An update on donor-derived disease transmission in organ transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011

Area of Science:

  • Transplantation Immunology
  • Oncology
  • Virology

Background:

  • Posttransplant lymphoproliferative disorders (PTLDs) are a spectrum of lymphoid conditions that develop in immunosuppressed organ transplant recipients.
  • A significant association exists between PTLDs and Epstein-Barr virus (EBV) infection, particularly within B lymphocytes.

Purpose of the Study:

  • To review the clinical and pathological features of PTLDs.
  • To clarify the terminology used for these lesions.
  • To outline current and experimental diagnostic and therapeutic strategies.

Main Methods:

  • Literature review of clinical and pathological aspects of PTLDs.
  • Summary of diagnostic criteria and therapeutic approaches.
  • Analysis of patient outcomes from published data.

Related Experiment Videos

Main Results:

  • PTLDs exhibit considerable clinical heterogeneity.
  • Diagnosis relies on a combination of clinical, pathological, and virological assessments.
  • Therapeutic strategies range from reducing immunosuppression to chemotherapy and targeted therapies.

Conclusions:

  • PTLDs represent a complex group of disorders requiring careful management.
  • Individualized treatment plans are essential due to the variability in presentation and patient response.
  • Further research into novel therapeutic approaches is warranted.